Clinical trials: TP53
Mitochondrial Disorders, Li-Fraumeni Syndrome
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
This study will examine metabolic and biological factors in people with Li-Fraumeni syndrome, a rare hereditary disorder that greatly increases a person's susceptibility to cancer.
- Conditions
- Mitochondrial Disorders, Li-Fraumeni Syndrome, Carriers of p53 Mutation
- Trial name
- NCT00406445
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Ropeginterferon, Alfa-2b
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations
To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations.
- Conditions
- Ropeginterferon, Alfa-2b, Azacitidine, MDS/AML
- Trial name
- NCT07646821
- Testing
- ropeginterferon alfa- 2b, Azacitidine (AZA)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult, Lung Adenocarcinoma
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
To evaluate the safety and efficacy of T cell therapy with mutated TP53 R248Q specific TCR transduction in patients with advanced solid tumor expressing the TP53 R248Q mutation and the HLA-A*11:01 allele.
- Conditions
- Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer, Colorectal Cancer
- Trial name
- NCT06619886
- Testing
- Autologous, engineered T Cells targeting TP53 R248Q
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Chronic Lymphocytic Leukemia in Relapse, Chronic Lymphocytic Leukemia in Remission
A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations
The aim of the current trial is to evaluate if combination treatment with venetoclax + ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (RR CLL) can lead to MRD negativity, which may induce long…
- Trial name
- NCT03226301
- Testing
- Ibrutinib + Venetoclax 15 cycles, Ibrutinib until progression/relapse, Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles
- Where
- 49 sites in Belgium, Denmark and 4 more
- Volunteers
- 230 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Polycythemia Vera, Essential Thrombocythemia
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to…
- Trial name
- NCT01970930
- Testing
- Blood specimen
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Colorectal Cancer, APC Gene Mutation
Patogenic Mutation in 5 Genes
This is a pathogenic mutation profile of colorectal patients specifically in 5 genes, i.e. APC, TP53, PIK3CA, KRAS, and MLH1. Single nucleotide variants identified were synchronized with patients' characteristics.
- Conditions
- Colorectal Cancer, APC Gene Mutation, TP53 Gene Mutation, PIK3CA Gene Mutation
- Trial name
- NCT04976439
- Testing
- co-occuring mutation
- Where
- Indonesia
- Volunteers
- 22 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Lung Neoplasms, Gene, p53
Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
p53 is a tumor suppressor gene which plays an important role in controlling normal cell proliferation regulation that is located on the chromosome 17 (17p13.1). It is the most common goal of genetic alteration in many tumors.
- Trial name
- NCT02309567
- Testing
- Blood Collection
- Where
- Turkey (Türkiye)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Cumhuriyet University
Education
Transition From Research to Disclosure in Human Genetics
The goal of this study is to design a means of providing research families, from diverse geographical locations, the chance to receive genetic testing after having been educated by video, and meetings or telephone conversations…
- Trial name
- NCT00505466
- Testing
- Genetic Counseling
- Where
- United States
- Volunteers
- 577 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Brain Tumor
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia.
- Conditions
- Leukemia, Brain Tumor, Solid Tumor, Lymphoma
- Trial name
- NCT03654716
- Testing
- ALRN-6924, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
P53 Mutation, Myeloid Malignancy
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
TP53 mutation is commonly associated with poor cancer patient prognosis yet no mutant p53 (mp53)-targeting regimen was clinically established.
- Conditions
- P53 Mutation, Myeloid Malignancy, MDS, Aml
- Trial name
- PANDA-T0 (NCT03855371)
- Testing
- Decitabine, Arsenic Trioxide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Ruijin Hospital
Hematologic Malignancy, Acute Leukemia
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia
- Trial name
- NCT05735717
- Testing
- Fludarabine, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
This is a phase 2, open-label, multicenter study evaluating the efficacy and safety of a fixed-duration combination of epcoritamab, venetoclax, and ibrutinib (EVI) in previously untreated patients with chronic lymphocytic…
- Trial name
- EVITA (NCT07738887)
- Testing
- Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab
- Where
- 29 sites in Belgium, France
- Volunteers
- 44 people
- Sponsor
- The Lymphoma Academic Research Organisation
P53 Mutation in Esophageal Cancer
ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance
Collect 300 esophageal cancer tissue specimens, including cancer tissue and serum, from a biological sample bank. Collect clinical information on esophageal cancer, including gender, age, time of diagnosis, time of death…
- Trial name
- NCT07722819
- Testing
- No intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ling Zhiqiang
Prevention of Chemotherapy-induced Myelosuppression
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
This is a Phase 1b open-label, single arm, multicenter, study of ALRN-6924 as a chemoprotection agent in patients with TP53-mutated HER2- breast cancer (stages IIa to IIIb) receiving neoadjuvant or adjuvant chemotherapy with…
- Trial name
- NCT05622058
- Testing
- ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
- Where
- 14 sites in United States, Bosnia and Herzegovina and 2 more
- Volunteers
- 6 people
- Sponsor
- Aileron Therapeutics, Inc.
Medulloblastoma Recurrent, Medulloblastoma, Childhood, Recurrent
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
The purpose of this study is to create a biobank for patients diagnosed with Sonic Hedgehog Medulloblastoma at Baylor College of Medicine/Texas Children's Cancer Center.
- Conditions
- Medulloblastoma Recurrent, Medulloblastoma, Childhood, Recurrent, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype
- Trial name
- NCT07242963
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Mohammad H. Abu Arja
Solid Tumor
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in participants with wild-type TP53 advanced solid tumors.
- Trial name
- NCT03975387
- Testing
- ASTX295
- Where
- 11 sites in United States
- Volunteers
- 106 people
- Sponsor
- Taiho Oncology, Inc.
Chronic Lymphocytic Leukemia
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the…
- Trial name
- NCT05197192
- Testing
- Obinutuzumab, Venetoclax, Acalabrutinib
- Where
- 30 sites in Germany
- Volunteers
- 202 people
- Sponsor
- German CLL Study Group
Mantle Cell Lymphoma (MCL)
Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL
FRONTIER is a prospective, single arm, open label, multi-center, Phase II study of MB-CART2019.1 (Zamtocabtagene Autoleucel) therapy as frontline consolidation for high-risk Mantle Cell Lymphoma (MCL) participants
- Trial name
- FRONTIER (NCT07569965)
- Testing
- zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine
- Volunteers
- 52 people
- Sponsor
- Miltenyi Biomedicine GmbH
DLBCL - Diffuse Large B Cell Lymphoma, TP53
AZA Combined With RCHOP in P53-mutated DLBCL.
To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
- Trial name
- NCT06158399
- Testing
- Azacitidine in combination with R-CHOP
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
This is a phase II study of preoperative chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced resectable oral cavity squamous cell cancer.
- Trial name
- NCT01914900
- Testing
- docetaxel, cisplatin, 5 fluorouracil
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano